Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Lineage Cell Therapeutics (LCTX) over the last 3 years, with Q1 2025 value amounting to $2.0 million.

  • Lineage Cell Therapeutics' Change in Acquisitions & Divestments changed N/A to $2.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 6385.46%. This contributed to the annual value of $7.0 million for FY2024, which is 8894.68% down from last year.
  • As of Q1 2025, Lineage Cell Therapeutics' Change in Acquisitions & Divestments stood at $2.0 million.
  • Lineage Cell Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $24.3 million during Q2 2023, with a 5-year trough of $18000.0 in Q2 2024.
  • For the 3-year period, Lineage Cell Therapeutics' Change in Acquisitions & Divestments averaged around $9.0 million, with its median value being $4.9 million (2023).
  • Examining YoY changes over the last 5 years, Lineage Cell Therapeutics' Change in Acquisitions & Divestments showed a top increase of 3173.32% in 2024 and a maximum decrease of 9992.6% in 2024.
  • Quarter analysis of 3 years shows Lineage Cell Therapeutics' Change in Acquisitions & Divestments stood at $9.8 million in 2023, then tumbled by 69.49% to $3.0 million in 2024, then plummeted by 33.33% to $2.0 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $2.0 million for Q1 2025, versus $3.0 million for Q4 2024 and $4.0 million for Q3 2024.